UK markets closed
  • FTSE 100

    +20.07 (+0.27%)
  • FTSE 250

    +5.36 (+0.03%)
  • AIM

    +2.68 (+0.32%)

    -0.0005 (-0.04%)

    -0.0023 (-0.19%)

    +59.49 (+0.44%)
  • CMC Crypto 200

    +4.32 (+1.13%)
  • S&P 500

    -1.14 (-0.03%)
  • DOW

    +152.97 (+0.45%)

    -1.66 (-2.13%)

    +8.40 (+0.48%)
  • NIKKEI 225

    -100.06 (-0.35%)

    -87.32 (-0.49%)
  • DAX

    +1.82 (+0.01%)
  • CAC 40

    +5.16 (+0.08%)

KOL Webinar on Genetic Blindness Points to Promise of Kiora’s Pioneering Solution--Clinical Data in Q1

EQS-News: Kiora Pharmaceuticals
KOL Webinar on Genetic Blindness Points to Promise of Kiora’s Pioneering Solution--Clinical Data in Q1
31.10.2022 / 13:01 CET/CEST
The issuer is solely responsible for the content of this announcement.

Retinitis pigmentosa (RP) is a cluster of genetic eye diseases that damage the retina, the light-sensitive layer of the eye. It typically affects people in their teens or 20s, although some variations initiate in children as young as 8.

There is currently no cure for the disease, and it inevitably leads to total blindness.

Stonegate Healthcare recently hosted an event focusing on the disease. “Battling Blindness in Retinitis Pigmentosa: A Discussion of Disease & the Pipeline of Hope” featured three speakers: Ben Shaberman of the Foundation Fighting Blindness, who provided a patient perspective, retinitis pigmentosa specialist Dr. Christine Kay, an inherited retinal disease specialist and Kiora Pharmaceuticals Inc.’s Chief Development Officer, Dr. Eric Daniels.

A Simple But Elegant Solution

RP has been a difficult disease for practitioners to tackle, and the U.S. Food and Drug Administration (FDA) has not approved any treatments to date specifically indicated for the condition. In many cases, the disease is diagnosed only after vision loss initiates.

According to Dr. Kay, mutations in more than 65 genes can cause RP and whilst gene therapy approaches offer promise to addressing RP, the FDA would have to essentially approve 65 unique gene therapy treatments to address all the patients with RP. Timing of diagnosis of RP may also present challenges, and for many patients, it may be too late to qualify for gene therapy treatment.

Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is a pharmaceutical company specializing in treating eye diseases with high unmet need. During the webinar, Dr. Daniels talked about the company’s novel treatment, KIO-301, which is in Phase 1b clinical trials. The study is expected to generate interim data before the end of this year, with top line results planned for the first quarter of 2023.

Dr. Daniels describes KIO-301 as a “simple but elegant solution” to RP. KIO-301 does not focus on the photoreceptors in the eye, which die in patients with RP, but instead turns its attention to the retinal ganglion cell (RGC – the cells that comprise the optic nerve). RGCs are still viable and functional in RP patients — it’s the photoreceptors (rods and cones) that are failing. KIO-301 specifically enters the RGCs in the eye and makes these cells light sensitive.

It is the hope that KIO-301 can restore significant visual functionality in patients with vision loss due to RP. The treatment does not interfere with native functional vision, which also makes it a potentially viable treatment for patients with less-advanced RP.

RP specialist Dr. Kay is hopeful and excited about Kiora’s clinical trials.

Patients Have Passion and Urgency For Treatment

Mr. Shaberman provided the patient’s perspective, indicating that people with RP are passionate about finding a treatment to address their blindness and are willing to participate in early stage clinical research of novel therapies to find one. Dr. Daniels said Kiora has a long list of patients from around the world who would like to be part of the company’s clinical trials.

What sets KIO-301 apart from other potential therapies, including gene therapy alternatives, is the ease of treatment. Dr. Kay said she is interested in KIO-301 because it is potentially safe, easy to administer and a reasonable approach to vision restoration. KIO-301 will be administered intravitreally, allowing most any ophthalmologists the capability to provide the treatment with no need for more invasive and expensive surgeries. The risk of infection is extremely low compared to other routes of administrations.

“For patients with RP, even partial restoration of their vision can be life-changing”, Mr. Shaberman said. “RP is an emotionally burdensome disease for patients and their families. KIO-301 gives hope to patients who are eagerly awaiting a solution to their blindness.”

To watch a recording of the event, click here.

Click here for more information on Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact Details

Thomas Redington

Company Website

News Source: News Direct

31.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at




Kiora Pharmaceuticals

United States



EQS News ID:



End of News

EQS News Service

show this
show this